Monitoring of 30 marker candidates in early Parkinson disease as progression markers

Neurology

Volumn 87, Issue 2, 2016, Pages 168-177

  Mollenhauer, Brit ^a,b   Zimmermann, Johannes ^c   Sixel Döring, Friederike ^a   Focke, Niels K ^c   Wicke, Tamara ^a   Ebentheuer, Jens ^a   Schaumburg, Martina ^a   Lang, Elisabeth ^a   Trautmann, Ellen ^a   Zetterberg, Henrik ^d,e   Taylor, Peggy ^f   Friede, Tim ^b   Trenkwalder, Claudia ^a,b  

^a PARACELSUS ELENA KLINIK   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f BIOLEGEND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN; TAU PROTEIN; URIC ACID; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; AUTONOMIC SCALE FOR OUTCOMES IN PARKINSON DISEASE; BECK DEPRESSION INVENTORY; BRAIN CORTEX; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; EPWORTH SLEEPINESS SCALE; EXPLORATORY RESEARCH; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEUROIMAGING; NEUROLOGIC DISEASE ASSESSMENT; NONMOTOR SYMPTOM SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PARKINSON DISEASE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REM SLEEP BEHAVIOR DISORDER SCREENING QUESTIONNAIRE; SLEEP DISORDER ASSESSMENT; UNIFIED PARKINSON DISEASE RATING SCALE; URIC ACID BLOOD LEVEL; VOXEL BASED MORPHOMETRY; BRAIN; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; PSYCHOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BIOMARKERS; BRAIN; DISEASE PROGRESSION; DOPAMINE AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYSOMNOGRAPHY; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84978945343     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002651     Document Type: Article

References (36)

1. Biglan KM, Holloway RG. Surrogate endpoints in Parkinson's disease research. Curr Neurol Neurosci Rep 2003;3:314-320
2. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
3. Investigators NN-P. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-28
4. Parkinson Study Group PI. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490
5. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610-622
6. Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson's disease a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 2013;84:14-17
7. HelyMA, Morris JG, ReidWG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20: 190-199
8. Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012;259:2621-2631
9. Zhang J, Mattison HA, Liu C, et al. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013;126:671-682
10. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-1171
11. Mollenhauer B, Trautmann E, Sixel-Doring F, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 2013; 81:1226-1234
12. Parkinson-Syndrome: Diagnostik und Therapie. Available at: http://www.dgn.org/leitlinien-online-2012/ inhalte-nach-kapitel/2346-ll-09-2012-parkinson-syndromediagnostik-und-therapie.html. Accessed October 6, 2015
13. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653
14. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23:2129-2170
15. Hanganu A, Bedetti C, Degroot C, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain 2014;137:1120-1129
16. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460-1468
17. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or Parkinsonian disorders. Arch Neurol 2012:1-8
18. Feingold A. Effect sizes for growth-modeling analysis for controlled clinical trials in the same metric as for classical analysis. Psychol Methods 2009;14:43-53
19. Maronna R, Martin D, Yohai V. Robust Statistics: Theory and Methods. New York: Wiley; 2006
20. R Core Team. R a Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing. Available at: http://www.R-project.org. Accessed June 1, 2013
21. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46
22. Sixel-Doring F, Schweitzer M, Mollenhauer B, Trenkwalder C. Intraindividual variability of REM sleep behavior disorder in Parkinson's disease a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med 2011;7:75-80
23. Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, et al. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. Eur J Neurol 2015;22:37-43
24. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013;136:1568-1577
25. Muslimovic D, Schmand B, Speelman JD, de Haan RJ. Course of cognitive decline in Parkinson's disease a metaanalysis. J Int Neuropsychol Soc 2007;13:920-932
26. Sixel-Doring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology 2011;77:1048-1054
27. Ataide M, Franco CM, Lins OG. Daytime sleepiness in Parkinson's disease: perception, influence of drugs, and mood disorder. Sleep Disord 2014;2014:939713
28. Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease a prospective cohort study. Neurology 2014;83:1253-1260
29. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24: 197-211
30. Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Temporal lobe atrophy on MRI in Parkinson disease with dementia a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005;64: 861-865
31. Stewart T, Liu C, Ginghina C, et al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol 2014;184:966-975
32. Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014;6:226ra230
33. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011;95:629-635
34. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism a cohort study. Lancet Neurol 2011;10:230-240
35. Sherman RA, Funder DC. Evaluating correlations in studies of personality and behavior: beyond the number of significant findings to be expected by chance. J Res Personality 2009;43:1053-1063
36. Smith KM, Eyal E, Weintraub D; ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015;72:88-95